There is little time left for Merck & Co Inc (MRK) to reach its 1-year target estimate. How soon will it surpass it?

Merck & Co Inc (NYSE:MRK) shares traded 0.26% higher at $127.99 on Wall Street last session.

MRK stock price is now 2.06% away from the 50-day moving average and 14.35% away from the 200-day moving average. The market capitalization of the company currently stands at $324.15B.

With the price target maintained at $104, Societe Generale recently Downgraded its rating from Hold to Sell for Merck & Co Inc (NYSE: MRK). On January 04, 2024, TD Cowen Upgraded its previous ‘Market Perform’ rating to ‘Outperform’ on the stock increasing its target price from $125 to quote $135, while ‘Deutsche Bank’ rates the stock as ‘Buy’

In other news, Merck & Co., Inc., 10% Owner bought 21,397,205 shares of the company’s stock on Mar 11 ’24. The stock was bought for $492,135,715 at an average price of $23.00. Upon completion of the transaction, the 10% Owner now directly owns 1,000 shares in the company, valued at $0.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 14 ’24, Chairman, CEO & President Davis Robert M sold 85,021 shares of the business’s stock. A total of $10,661,574 was realized by selling the stock at an average price of $125.40. This leaves the insider owning 348,327 shares of the company worth $44.58 million. A total of 0.15% of the company’s stock is owned by insiders.

During the past 12 months, Merck & Co Inc has had a low of $99.14 and a high of $133.10. As of last week, the company has a debt-to-equity ratio of 0.97, a current ratio of 1.25, and a quick ratio of 1.00. According to the stock market information, the enterprise value for the company is $352.12B, which is based on a 968.15 price-to-earnings ratio, a 14.33 price-to-earnings-growth ratio, and a beta of 0.41. The fifty day moving average price for MRK is $125.59 and a two-hundred day moving average price translates $112.01 for the stock.

The latest earnings results from Merck & Co Inc (NYSE: MRK) was released for Dec, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $0.03, beating analysts’ expectations of -$0.11 by 0.14. This compares to $1.18 EPS in the same period last year. The net profit margin was 0.61% and return on equity was 0.87% for MRK. The company reported revenue of $14.63 billion for the quarter, compared to $13.83 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.79 percent. For the current quarter, analysts expect MRK to generate $15.13B in revenue.

Related Posts